<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; acquisitions</title>
	<atom:link href="http://www.tapanray.in/tag/acquisitions/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDI in ‘Brownfield’ Pharma acquisitions and the growth of ‘Greenfield’ projects in India</title>
		<link>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india</link>
		<comments>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/#comments</comments>
		<pubDate>Sat, 17 Sep 2011 00:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[projects]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=200</guid>
		<description><![CDATA[Just when global multinational companies are inking deals to get more and more drugs manufactured in India, because of various financial and other considerations, giving a fillip to the domestic manufacturing capacity, recent media reports are carrying news items expressing &#8230; <a href="http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Could M&amp;As in Pharma create significant stakeholder value?</title>
		<link>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=could-mas-in-pharma-create-significant-stakeholder-value</link>
		<comments>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/#comments</comments>
		<pubDate>Mon, 25 Apr 2011 01:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[consolidation]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=269</guid>
		<description><![CDATA[At the very outset, I pay my homage to the departed soul of our industry colleague respected Amar Lulla, former joint managing director of Cipla, who passed away on Friday, April 22, 2011 after a prolonged battle against cancer. As &#8230; <a href="http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A time to keep our nose to the Grindstone &#8211; Competition Act will take care of M&amp;As, come June 2011</title>
		<link>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011</link>
		<comments>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/#comments</comments>
		<pubDate>Mon, 14 Mar 2011 00:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[come]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[Grindstone]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[June]]></category>
		<category><![CDATA[keep]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[nose]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[our]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[take]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=290</guid>
		<description><![CDATA[Full control of powers on Mergers and Acquisitions of the Competition Commission of India (CCI) effective June 1, 2011, has now been notified. In this evolving scenario, it is indeed difficult to understand, why is the FDI issue on M&#38;A &#8230; <a href="http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
